Recent Advances in Tissue plasminogen activator-based nanothrombolysis for ischemic stroke
Stroke is an acute cerebrovascular disorder caused by sudden decrease or interruption of blood flow in brain arteries. Deficiency of timely and effective reperfusion of ischemic brain tissue can lead to irreversible brain injury and neurological dysfunction. Currently, recombinant tissue plasminogen...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
De Gruyter
2019-09-01
|
| Series: | Reviews on Advanced Materials Science |
| Subjects: | |
| Online Access: | https://doi.org/10.1515/rams-2019-0024 |
| _version_ | 1818668990668472320 |
|---|---|
| author | Huang Dongdong Wu Ke Zhang Ying Ni Zhihui Zhu Xiaohong Zhu Can Yang Jianjing ZhuGe Qichuan Hu Jiangnan |
| author_facet | Huang Dongdong Wu Ke Zhang Ying Ni Zhihui Zhu Xiaohong Zhu Can Yang Jianjing ZhuGe Qichuan Hu Jiangnan |
| author_sort | Huang Dongdong |
| collection | DOAJ |
| description | Stroke is an acute cerebrovascular disorder caused by sudden decrease or interruption of blood flow in brain arteries. Deficiency of timely and effective reperfusion of ischemic brain tissue can lead to irreversible brain injury and neurological dysfunction. Currently, recombinant tissue plasminogen activator (rt-PA) is the only appropriate thrombolytic agent which is approved by FDA for patients with acute ischemic stoke. However, due to the limitation of very narrow therapeutic time window and severe intracranial hemorrhagic complication, the outcome of stroke treatment mediated by rt-PA still remains unsatisfactory. Therefore, it is urgent to find new alternative drugs or develop novel drug delivery system to achieve better outcomes. In recent years, with the rapid development of nanotechonology, nanomaterials as a drug delivery system can provide new strategies and methods to carry t-PA specifically to the occlusion site and provide advanced treatment for stroke. In this review, we briefly introduced the physiopathologic mechanisms of thrombolysis and focused on the comparison of the t-PA mediated thrombolysis and t-PA conjugated nanomaterial mediated thrombolysis. |
| first_indexed | 2024-12-17T06:45:06Z |
| format | Article |
| id | doaj.art-bc14043bd04a415e8e86339f9e590059 |
| institution | Directory Open Access Journal |
| issn | 1605-8127 |
| language | English |
| last_indexed | 2024-12-17T06:45:06Z |
| publishDate | 2019-09-01 |
| publisher | De Gruyter |
| record_format | Article |
| series | Reviews on Advanced Materials Science |
| spelling | doaj.art-bc14043bd04a415e8e86339f9e5900592022-12-21T21:59:46ZengDe GruyterReviews on Advanced Materials Science1605-81272019-09-0158115917010.1515/rams-2019-0024Recent Advances in Tissue plasminogen activator-based nanothrombolysis for ischemic strokeHuang Dongdong0Wu Ke1Zhang Ying2Ni Zhihui3Zhu Xiaohong4Zhu Can5Yang Jianjing6ZhuGe Qichuan7Hu Jiangnan8Department of Neurosurgery, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou325000, China; Zhejiang Provincial Key Laboratory of Aging and Neurological Disorder Research, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou325000, ChinaDepartment of Neurosurgery, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou325000, China; Zhejiang Provincial Key Laboratory of Aging and Neurological Disorder Research, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou325000, ChinaDepartment of Neurosurgery, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou325000, China; Zhejiang Provincial Key Laboratory of Aging and Neurological Disorder Research, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou325000, ChinaDepartment of Neurosurgery, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou325000, China; Zhejiang Provincial Key Laboratory of Aging and Neurological Disorder Research, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou325000, ChinaDepartment of Neurosurgery, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou325000, China; Zhejiang Provincial Key Laboratory of Aging and Neurological Disorder Research, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou325000, ChinaDepartment of Neurosurgery, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou325000, China; Zhejiang Provincial Key Laboratory of Aging and Neurological Disorder Research, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou325000, ChinaDepartment of Neuro-surgery, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou325000, China; Zhejiang Provincial Key Laboratory of Aging and Neurological Disorder Research, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou325000, ChinaDepartment of Neuro-surgery, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou325000, China; Zhejiang Provincial Key Laboratory of Aging and Neurological Disorder Research, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou325000, ChinaDepartment of Neuro-surgery, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou325000, China; Zhejiang Provincial Key Laboratory of Aging and Neurological Disorder Research, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou325000, China; Department of Pharmacology and Neuroscience, University of North Texas Health Science Center, Fort Worth, Texas76107, United States of AmericaStroke is an acute cerebrovascular disorder caused by sudden decrease or interruption of blood flow in brain arteries. Deficiency of timely and effective reperfusion of ischemic brain tissue can lead to irreversible brain injury and neurological dysfunction. Currently, recombinant tissue plasminogen activator (rt-PA) is the only appropriate thrombolytic agent which is approved by FDA for patients with acute ischemic stoke. However, due to the limitation of very narrow therapeutic time window and severe intracranial hemorrhagic complication, the outcome of stroke treatment mediated by rt-PA still remains unsatisfactory. Therefore, it is urgent to find new alternative drugs or develop novel drug delivery system to achieve better outcomes. In recent years, with the rapid development of nanotechonology, nanomaterials as a drug delivery system can provide new strategies and methods to carry t-PA specifically to the occlusion site and provide advanced treatment for stroke. In this review, we briefly introduced the physiopathologic mechanisms of thrombolysis and focused on the comparison of the t-PA mediated thrombolysis and t-PA conjugated nanomaterial mediated thrombolysis.https://doi.org/10.1515/rams-2019-0024tissue plasminogen activatordrug deliverynanomaterialstrokethrombolysis |
| spellingShingle | Huang Dongdong Wu Ke Zhang Ying Ni Zhihui Zhu Xiaohong Zhu Can Yang Jianjing ZhuGe Qichuan Hu Jiangnan Recent Advances in Tissue plasminogen activator-based nanothrombolysis for ischemic stroke Reviews on Advanced Materials Science tissue plasminogen activator drug delivery nanomaterial stroke thrombolysis |
| title | Recent Advances in Tissue plasminogen activator-based nanothrombolysis for ischemic stroke |
| title_full | Recent Advances in Tissue plasminogen activator-based nanothrombolysis for ischemic stroke |
| title_fullStr | Recent Advances in Tissue plasminogen activator-based nanothrombolysis for ischemic stroke |
| title_full_unstemmed | Recent Advances in Tissue plasminogen activator-based nanothrombolysis for ischemic stroke |
| title_short | Recent Advances in Tissue plasminogen activator-based nanothrombolysis for ischemic stroke |
| title_sort | recent advances in tissue plasminogen activator based nanothrombolysis for ischemic stroke |
| topic | tissue plasminogen activator drug delivery nanomaterial stroke thrombolysis |
| url | https://doi.org/10.1515/rams-2019-0024 |
| work_keys_str_mv | AT huangdongdong recentadvancesintissueplasminogenactivatorbasednanothrombolysisforischemicstroke AT wuke recentadvancesintissueplasminogenactivatorbasednanothrombolysisforischemicstroke AT zhangying recentadvancesintissueplasminogenactivatorbasednanothrombolysisforischemicstroke AT nizhihui recentadvancesintissueplasminogenactivatorbasednanothrombolysisforischemicstroke AT zhuxiaohong recentadvancesintissueplasminogenactivatorbasednanothrombolysisforischemicstroke AT zhucan recentadvancesintissueplasminogenactivatorbasednanothrombolysisforischemicstroke AT yangjianjing recentadvancesintissueplasminogenactivatorbasednanothrombolysisforischemicstroke AT zhugeqichuan recentadvancesintissueplasminogenactivatorbasednanothrombolysisforischemicstroke AT hujiangnan recentadvancesintissueplasminogenactivatorbasednanothrombolysisforischemicstroke |